Deerfield wins sweetened bid to acquire NitroMed
After upping the ante twice, investment firm Deerfield Management has won its latest bid to acquire nitric oxide therapeutics biotech NitroMed for $0.80 in cash for each outstanding share--60% higher than its original offer--or about $36.8mm (over twice NitroMed's 2007 sales).
- Full Acquisition
- Includes Contract
- Payment Includes Cash for Equity
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com